Skip to main content
Erschienen in: World Journal of Urology 1/2016

01.01.2016 | Original Article

Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?

verfasst von: Laura-Maria Krabbe, Aditya Bagrodia, Mary E. Westerman, Bishoy A. Gayed, Ahmed Q. Haddad, Arthur I. Sagalowsky, Shahrokh F. Shariat, Payal Kapur, Yair Lotan, Vitaly Margulis

Erschienen in: World Journal of Urology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the potential biologic impact of tumor location on oncological outcomes for patients with upper tract urothelial carcinoma (UTUC), we used prospectively collected molecular signatures of high-grade UTUC.

Methods

Immunohistochemical staining for p21, p27, p53, cyclin E, and Ki-67 was prospectively performed on 96 UTUC specimens of patients with non-metastatic high-grade UTUC treated with extirpative surgery. Patients were grouped according to primary tumor location (pelvicalyceal vs. ureteral) where primary tumor was defined as the highest tumor stage and diameter. Primary outcome was assessment of differences in marker expression between groups. Secondary outcome was difference in survival according to marker status.

Results

Pelvicalyceal and ureteral tumors were found in 52.1 and 47.9 %, respectively, and 42.7 % of patients had non-organ-confined disease. Over a median follow-up of 22.0 months, 31.2 and 20.8 % of patients experienced disease recurrence and died of UTUC, respectively. The total number of altered markers stained for was 0–2 in 67.7 and 3–5 in 32.3 % of patients. The number of altered markers and alteration status of markers were not significantly different between patients with primary pelvicalyceal versus ureteral tumors when stratified by tumor stage and nodal status. There were no significant differences in survival outcomes between both groups when stratified by number of altered markers (0–2 and 3–5).

Conclusions

The prospective assessment of selected cell cycle and proliferative markers suggests no molecular difference between UTUC of the pelvicalyceal system and that of the ureter. Our study is limited by its size and definition of location.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Munoz JJ, Ellison LM (2000) Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 164:1523–1525PubMedCrossRef Munoz JJ, Ellison LM (2000) Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 164:1523–1525PubMedCrossRef
2.
Zurück zum Zitat Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458PubMedCrossRef Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458PubMedCrossRef
3.
Zurück zum Zitat Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114PubMedCrossRef Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114PubMedCrossRef
4.
Zurück zum Zitat Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82PubMedPubMedCentralCrossRef Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat van der Poel HG, Antonini N, van Tinteren H, Horenblas S (2005) Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 48:438–444PubMedCrossRef van der Poel HG, Antonini N, van Tinteren H, Horenblas S (2005) Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 48:438–444PubMedCrossRef
6.
Zurück zum Zitat Park J, Ha SH, Min GE, Song C, Hong B, Hong JH et al (2009) The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol 182:894–899PubMedCrossRef Park J, Ha SH, Min GE, Song C, Hong B, Hong JH et al (2009) The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol 182:894–899PubMedCrossRef
7.
Zurück zum Zitat Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef
8.
Zurück zum Zitat Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K et al (2010) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K et al (2010) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef
9.
Zurück zum Zitat Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580PubMedPubMedCentralCrossRef Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef
11.
Zurück zum Zitat Milojevic B, Djokic M, Sipetic-Grujicic S, Milenkovic-Petronic D, Vuksanovic A, Bumbasirevic U et al (2012) Upper urinary tract transitional cell carcinoma: location is not correlated with prognosis. BJU Int 109:1037–1042PubMedCrossRef Milojevic B, Djokic M, Sipetic-Grujicic S, Milenkovic-Petronic D, Vuksanovic A, Bumbasirevic U et al (2012) Upper urinary tract transitional cell carcinoma: location is not correlated with prognosis. BJU Int 109:1037–1042PubMedCrossRef
12.
Zurück zum Zitat Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ et al (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13PubMedCrossRef Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ et al (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13PubMedCrossRef
13.
Zurück zum Zitat Zhang X, Zhu Z, Zhong S, Xu T, Shen Z (2013) Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol 31:155–160PubMedCrossRef Zhang X, Zhu Z, Zhong S, Xu T, Shen Z (2013) Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol 31:155–160PubMedCrossRef
14.
Zurück zum Zitat Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H et al (2014) Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol 21(3):1038–1045PubMedCrossRef Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H et al (2014) Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol 21(3):1038–1045PubMedCrossRef
15.
Zurück zum Zitat Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y et al (2013) Prospective evaluation of a molecular marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. Eur Urol 64(3):465–471PubMedCrossRef Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y et al (2013) Prospective evaluation of a molecular marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. Eur Urol 64(3):465–471PubMedCrossRef
16.
Zurück zum Zitat Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF et al (2014) Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? J Urol 191(4):926–931PubMedCrossRef Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF et al (2014) Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? J Urol 191(4):926–931PubMedCrossRef
17.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York
18.
Zurück zum Zitat Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M et al (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059–1071PubMedCrossRef Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M et al (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059–1071PubMedCrossRef
19.
Zurück zum Zitat Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854–855PubMedCrossRef Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854–855PubMedCrossRef
20.
Zurück zum Zitat Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF et al (2014) Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review of the literature. J Urol 191(1):28–34PubMedCrossRef Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF et al (2014) Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review of the literature. J Urol 191(1):28–34PubMedCrossRef
21.
Zurück zum Zitat Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ et al (2008) Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112:315–325PubMedCrossRef Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ et al (2008) Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112:315–325PubMedCrossRef
Metadaten
Titel
Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?
verfasst von
Laura-Maria Krabbe
Aditya Bagrodia
Mary E. Westerman
Bishoy A. Gayed
Ahmed Q. Haddad
Arthur I. Sagalowsky
Shahrokh F. Shariat
Payal Kapur
Yair Lotan
Vitaly Margulis
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1584-6

Weitere Artikel der Ausgabe 1/2016

World Journal of Urology 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.